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Summary. Prothrombin deficiency is a rare (1:200 000)
autosomal recessive disorder caused by diverse mutations in
prothrombin gene. We have studied the molecular basis of this
disorder in four unrelated Indian patients. The diagnosis was
based on prolonged prothrombin (PT) and activated partial
thromboplastin times and low factor II coagulant activity
(FII: C) measured using a PT based assay. FII: C levels ranged
between 4.7% and 17.5%. Mutations were identified in all the
four patients. Five different causative mutations including four
(80%)missense and an in-frame deletion (20%)were identified.
One of them was a novel, Ala362 fi Thr aminoacid change
affecting B chain of a-thrombin. This mutation was present in
a compoundheterozygous statewith a previously reportedArg-
1 fi Gln missense change affecting pro-peptide cleavage site.
Ala362 fi Throccurred at a codon, evolutionarily conserved in
all the 24 different prothrombins or its related serine proteases
studied. Molecular modeling of this mutation was found to
cause a conformational change around the region involving a
catalytic triad residue His363 and a cysteine residue at codon
364. The FII: C level in this patient was 17.5%. Three other
previously reported mutations were also detected in the
homozygous state: Arg271 fi Cys in Kringle-2 region, a
Glu309 fi Lys in A chain of a-thrombin and an in-frame
deletion of 3 bp (AAG) leading to Del Lys301/302 in A chain
of a-thrombin. This is the first report of the molecular basis of
prothrombin deficiency in Indian patients and we suggest the
eponym ProthrombinVellore 1 for Ala362 fi Thrmutation.
Keywords: conformation sensitive gel electrophoresis, India,
prothrombin deficiency.
Introduction
Prothrombin (factor II) is a vitamin-K dependent glycoprotein
synthesized in liver and circulates in plasma at concentrations
of 1–2 lM. It is a precursor of the serine protease thrombin, a
central enzyme in the process of hemostasis and thrombosis
that exhibits both pro- and anticoagulant activities [1].
Prothrombin is activated by factor Xa in the presence of
phospholipids, calcium and factor Va to form thrombin that
converts fibrinogen to insoluble fibrin [1]. Thrombin promotes
blood coagulation by stimulating platelet aggregation and
activating factors V, VIII and XIII. It also inhibits coagulation
by activating protein C and thrombomodulin. Thrombin has
additional properties including cell proliferation [2,3] chemo-
taxis [4], tissue repair and angiogenesis [5,6].
Prothrombin is encoded by a gene which is 21 kb in length
and located in chromosome 11p11-q12 [7,8]. It is composed of
14exons separatedby13 introns [7].This gene is transcribed into
a prepropeptide containing protein of 622 aminoacids. Exons 1
and 2 encode the prepropeptide region (residues )43 to )1),
exons 2 and 3 encode the c-carboxyglutamic acid (Gla) domain
(residues 1–40), exons 3–7 for kringle-1 domain (residues
41–155) and exons 7 and 8 for kringle-2 domain (residues
156–271).Exons8–9 (residues272–320) encode the light chainof
thrombin and exons 9–14 encode the catalytic serine protease
domain (residues 321–579). Prothrombin is activated by factor
Xa by cleavage at Arg271-Thr272 and Arg320-Ile321 and by
a-thrombin by cleavage at Arg284-Thr285. The resulting
a-thrombin molecule is composed of an A-chain (Thr285-
Arg320) bridged to a B-chain (Ile321-Glu579) by a disulfide
bond formed by Cys293-Cys439. Mutations affecting most
of these domains have been reported to cause prothrombin
deficiency [9–11].
Congenital deficiency of prothrombin is an extremely rare
autosomal recessive bleeding disorder affecting 1:2 000 000 in
the general population [10]. Bleeding symptoms vary from
severe spontaneous life or limb threatening hemorrhages or to
mild presentations such as nose bleeding, menorrhagia and
post-traumatic/surgical bleeding only [9,10]. Often there is a
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discrepancy between the clinical severity of this disease and
antigen levels or coagulant activity [9]. The molecular basis of
this disease appears to be diverse in the few (n ¼ 34) mutations
characterized in prothrombin gene so far [11]. A vast majority
of them are missense mutations (79%, n ¼ 27) although
insertion/deletions (12%, n ¼ 4/34), nonsense (6%, n ¼ 2) and
splice site (3%, n ¼ 1) mutations have also been described [11].
Identification of additional mutations in this gene is important,
as they constitute naturally occurring models for studying the
molecular basis of this disease and to understand the effect of
these mutations on the function of thrombin, a key enzyme in
blood coagulation. Moreover, such data can also help in
precise genetic diagnosis and genetic counseling in families
affected by this disorder. Currently, most of the mutational
data available in the literature has come from patients of
Caucasian [9,12–18], Middle Eastern [9] or Oriental [19,20]
origin. In populations (South India) where consanguineous
marriages are often customary, the frequency of such reces-
sively inherited coagulation disorders in homozygosity is
significantly (eight- to 10-fold) increased [21]. We report here
for the first time, the clinical, phenotypic and molecular data in
Indian patients with congenital prothrombin deficiency.
Patients and methods
Patients
Genomic DNA from four unrelated South-Indian patients was
studied after informed consent. Their clinical severity was
graded as described [9]. Severe bleeders were those with a
history of spontaneous life or limb threatening bleedings such
as hemarthroses, hematomas, GI and CNS bleedings. Mild
bleeders were those who bled only after trauma or surgery or
had epistaxis, easy bruisability or menorrhagia.
Factor II assays
Prothrombin time (PT) and activated partial thromboplastin
time (APTT) were measured on a CA1500 automated analyzer
(Sysmex, Hyogo, Japan). FII coagulant (FII: C) activity was
determined by a prothrombin time based one-stage assay using
FII deficient plasma and recombinant human thromboplastin
(Innovin, Dade Behring, Marburg, Germany). FII antigen
levelswerenotdetermined inanyof thesepatients,becauseof the
non-availability of appropriate samples at the time of this study.
Prothrombin gene amplification
Prothrombingene exonicand theirflanking intronic regionsand
3¢ untranslated (UTR) region was amplified by 12 pairs of
primers (Table 1) designed by Primer3 software (http://
frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Polym-
erase chain reaction (PCR) was performed in a 25 lL reaction
volume containing 7.5 pmoles of each primer in a 1X concen-
tration of a ready reaction mix (ABgene, Epsom, UK)
containing 1.5 mM MgCl2, 75 mM Tris HCl (pH 8.8), 20 mM
(NH)2SO4, 0.2 mMof eachof dNTP, 0.01%(v/v)Tween 20 and
1.25 units of Thermoprime plus DNA polymerase. Approxi-
mately 250 ng of genomic DNA was used for amplification
reactions. Following an initial denaturation at 94 C for 5 min,
30 cycles of PCR amplification was performed, with dena-
turation at 94 C for 40 s, annealing at 58 C for 40 s and
extension at 72 C for 40 s. The final extensionwas at 72 C for
5 min.
Conformation sensitive gel electrophoresis
Heteroduplexes were prepared bymixing 5 lL of PCRproduct
from each patient with 5 lL of PCR product from a normal
control. Samples were denatured by heating to 95 C for 8 min
and then incubated at 50 C for 45 min to allow heteroduplex
formation [22]. Three to five microliters of heteroduplexed
samples were mixed with 1.5 lL of loading buffer (70%
glycerol, 0.1% xylene cyanol, 0.1% bromophenol blue, 0.01%
1 M EDTA) and electrophoresed in a mildly denaturing gel
(400 · 330 · 1 mm in size) containing 10% acrylamide [99.1
acrylamide (Invitrogen Lifetechnolgies, Groningen, The
Netherlands): bisacrolylpiperazine (Fluka Chemie, Buchs,
Switzerland)], 10% ethylene glycol (Sigma, St Louis, MO,
USA), 15% formamide (Sigma) and 0.5X TTE buffer [20X
TTE -1.78 M Tris (USB, Cleveland, OH, USA), 570 mM
Taurine (USB), 4 mM EDTA (USB)] as described previously
[22]. Polymerization was achieved by the addition of 0.1%
ammonium persulphate (USB), and 0.07% N, N, N¢, N¢–
tetramethylethylenediamine (TEMED) (Sigma). Following
electrophoresis at 400 V for 18 h, bands were visualized by
ethidium bromide staining.
DNA sequencing
Samples displaying abnormal conformation sensitive gel elec-
trophoresis (CSGE) patterns were sequenced by the Big Dye
Terminator cycle sequencing kit (Applied Biosystems, War-
rington, UK) on an ABI 310 genetic analyzer (PE Applied
Biosystems, Foster City, CA, USA) using the same primers
described for PCR (Table 1). Mutation nomenclature in
prothrombin gene was used as previously described [7].
Structural analysis of a novel missense mutation
A novel missense mutation was studied based on the coordi-
nates (identifier 1 ppb) for the human a-thrombin or on the
representational structure of human prothrombin [9] created
using crystal structures of human a-thrombin (PDB: 1 ppb),
bovine prothrombin fragment 1 (PDB: 2 hpq), human pro-
thrombin fragment 2 (PDB: 2pf2) deposited with the protein
data bank. The potential effects of this aminoacid substitution
was modeled by SwissPdb Viewer software [23]. The final
images were created by ViewerPro 4.2 software (Accelrys,
http://www.accelrys.com).
The aminoacid sequences of prothrombins from 17 different
species and seven related proteases were obtained from
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SwissProt and Trembl databases (http://us.expasy.org/sprot/)
using PSI-BLAST to study the conservation of an aminoacid
mutated by missense change. Their accession numbers are as
follows: P00734 – human prothrombin precursor; P08709 –
human coagulation factor VII precursor; P00740 – human
coagulation factor IX precursor; P00742 – human coagulation
factor X precursor; Q15146 – human plasminogen precursor;
P04070 – human protein C precursor; P22891 – human protein
Z precursor; P08519 – human apolipoprotein (a) precursor;
Q7SXH8 – zebra fish hypothetical protein; Q91218 – thrombin,
Oncorhynchus mykiss; Q90244 – thrombin, Acipenser trans-
montanus; Q804W7 – prothrombin precursor, Fugu rubripes;
P00735 – bovine prothrombin precursor; AAR99595 – coagu-
lation factor II, Sus scrofa; P19221 – mouse prothrombin
precursor; P18292 – rat prothrombin precursor; Q91001 –
chicken thrombin; Q9PTW7 – ostrich prothrombin; Q90WP0
– thrombin, Trachemys scripta elegans; Q90WT4 – African
crocodile putative thrombin; Q90WS2 – putative thrombin,
Elaphe sp.; Q91004 – thrombin, Gecko gecko; Q90387 –
thrombin, Cynops pyrrhogaster; Q90504 – Pacific hagfish
thrombin. Multiple sequence alignment was performed with
CLUSTALW (http://www.ebi.ac.uk/clustalw/).
Results
Patients
The clinical features and hematological parameters of the
patients are described in Table 2. Bleeding symptoms included
easy bruisability, post-traumatic bleeds, hemarthroses (50%
each), epistaxis, gum bleeding, menorrhagia, dental extraction
bleeding, hematemesis and hematomas (25% each). None of
them had spontaneous severe bleeding. BL-90 and BL-156 had
post-traumatic bleeding only. The clinical presentation in two
patients did not correlate with FII: C. Severe bleeding
symptoms were seen in-patient BL-154 with a coagulant
activity of 10.2%. She had pubertal menorrhagia and had
required multiple units of fresh blood during her first two
childbirths. She had aborted during her third pregnancy
following which the bleeding was unabated. It had required
an emergency total abdominal hysterectomy with transfusion
support. She had fractured her right femur following a fall
4 years ago. A open reduction and internal fixation was
planned elsewhere but could not be carried out because of
severe bleeding which had been managed by fresh blood and
fresh frozen plasma transfusion. The swelling in the right leg
had increased progressively and she presented to us with a
pseudo-tumor in right lower limb (Fig. 1). On evaluation she
was found to have prothrombin deficiency. Patient BL-156 had
a mild clinical phenotype with a reduced FII: C of 7.8%.
Mutation analysis
The PCR products from the patients mixed with normal
controls were indistinguishable on agarose gels (data not
shown). This suggested that only single base changes or
micro-deletions/insertions were likely. CSGE based mutation
screening and DNA sequencing identified four of five disease
causing mutations and 10 different polymorphisms (Table 2).
A G fi A transition in the heterozygous condition at
nucleotide 8825 and responsible for Ala362 fi Thr mutation
was not identified by CSGE. This mutation was detected by
complete gene sequencing. The low sensitivity of CSGE to
detect such G fi A (C fi T on reverse strand) transitions
has been reported [24]. Of the 10 different polymorphisms
identified, two (4282A fi G, 4304insG) were novel. The
remaining 8 (459delT, 554A fi G, 4048T fi C, 4125C fi G,
4203C fi T, 4272G fi A, 4291A fi G, 4298A fi G) poly-
morphisms have been essentially described among Japanese
[25,26] or Italian [12] patients. Most (6 of 8) of them
occurred in a region containing exon 6 and introns E and F
(nucleotides 4048–4303) that has been known to have high
sequence variability [25]. Apart from these nucleotide vari-
ations, five different disease-causing mutations were also
found in four unrelated patients (Fig. 2). Four (80%) of
them were missense and one (20%) was an in-frame deletion.
One of them was a novel mutation.
Novel mutation
A novel G fi A transition at nucleotide position 8825 in exon
10 in a heterozygous state was identified in one of the patients
Table 1 Primers used for amplification and sequencing of prothrombin gene
Exon Forward primer (5¢-3¢) Reverse primer (5¢-3¢) Amplicon size (bp)
F2-EXON 1 ACCCTCTCCGCTGATTTCTT GCCCTGAGCTCCTGACTTCT 323
F2-EXON 2 F AGGGTGGGCTTGCTTCAT CTCGCTTGCTTCTCTGTGG 326
F2-EXON 3 + 4 F AAACAACACAAAACAGGAGCTG CAAGCTCCCCTCCATGTC 420
F2-EXON 5 F CAACTTTGCAGGGAGAGAGG GCGGCAGAAATTCTCCTGTA 321
F2-EXON 6 F GAGAACAGGGAGCAAGCGTA TGTGCCTGGGTAGCCAGTAT 300
F2-EXON 7 F GTCTGTTCCGGTCCATGTGT AGGATTTGTCCCTGCAACTC 421
F2-EXON 8 + 9 F CTAGGGGATGGGTGAGGAAT CCCCCAGGAGTGAATGGTAG 439
F2-EXON 10 F GGGTTCTTAGACCTGGGATTG GATCGCTTTGGAGGACTCAG 317
F2-EXON 11F CTGTCTCCCAGAACCCCAAG AGAGCCAGGCCCAGAACT 322
F2-EXON 12F CCAGCTCTGGCGTTTTAGAT CTTGAACCCAGGCACAACTC 358
F2-EXON 13F TGTGTAGGGTGAGGAAGTGG GTATTCCTCTGCCAGGCAAC 300
F2-EXON 14 + 3UTR F TGATGTGACCTTGAACTTGACTC CAGAGAGCTGCCCATGAATAG 332
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(BL-90). This predicts the replacement of alanine-362 by
threonine in B-chain of a-thrombin.
Reported mutations
In the pro-peptide sequence in exon 2 of prothrombin gene, a
514G fi A transition was responsible for an Arg-1fi Gln
missense change. This mutation had occurred in a compound
heterozygous state with an Ala362 fi Thr mutation in patient
BL-90. An Arg271 fi Cys aminoacid change detected in
patient BL-154 corresponds to Kringle-2 region. This substi-
tution arises because of a 7311C fi T transition in a homo-
zygous form in exon 8. The remaining two reported mutations
were present in a homozygous condition in exon 9 and affected
the A chain of a-thrombin (Fig. 3). An in frame-deletion of
3 bp (7484/7489 del GAA) leading to deletion of one of either
Lys301 or Lys302 was present in patient BL-75. The second
mutation in this region was a Glu309 fi Lys (Prothrombin
Denver) aminoacid change caused by a 7509G fi A trans-
ition (BL-156).
Discussion
Congenital abnormalities of prothrombin are rare. Only 34
different mutations in this gene have been characterized so far
[11]. This is also the first study describingmutations in this gene
from India. Only two other large studies – one including
Italian, Iranian [9] and the other with patients from Puerto
Rico [13] population describing patients with prothrombin
deficiency have been published. Our strategy for the identifi-
Fig. 1. (A) The clinical photograph of pseudo-tumor of right thigh in
patient BL-154; (B) the radiological picture of destruction of right femur
by this pseudo-tumor; (C) the destruction of right-sided pelvic joint in this
patient.
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Fig. 2. Schematic representation of prothrombin gene mutations identi-
fied in this study.
1450 G. Jayandharan et al
 2005 International Society on Thrombosis and Haemostasis
cation of causal mutations was to screen for mutations by a
new CSGE based method followed by DNA sequencing. The
exonic and their flanking intronic regions and 3¢UTR regions in
the prothrombin genes of the proposita were screened, as these
are most likely sites for mutations that would affect transcrip-
tion or translation. Causative mutations were identified in each
of these patients. All but one patient had homozygous
mutations permitting the identification of the clinical conse-
quence of such mutations.
Of the five different causative mutations identified (Fig. 2),
four were missense and the other an in-frame deletion (7484/
7489 del GAA) in exon 9. None of these mutations are
predicted to result in a truncated protein or no protein at all.
This is in agreement with previous mutation data [9] and
consistent with the hypothesis that a complete absence of
prothrombin is incompatible with life as has been demonstra-
ted in a knockout mice model [27]. A majority of mutations
detected in this series were present in catalytic domain (60%)
emphasizing the functional importance of this region. Muta-
tions were also located in Pro-peptide (20%) and Kringle-2
(33%) domains suggesting that all these regions are important
in maintaining the overall structure and function of prothrom-
bin. One of these mutations identified in the catalytic domain
was novel.
The novel 8825G fi A mutation was responsible for an
alanine to threonine change at codon 362. As this is the first
report of the molecular basis of prothrombin deficiency in
Indian patients, we propose the eponym Prothrombin Vellore
1 for Ala362 fi Thr mutation. This mutation did not result in
alternate splicing as predicted by the splice site predic-
tion program (http://www.fruitfly.org/seq_tools/splice.html).
Ala362 fi Thrmutation is locatedwithin the histidine disulfide
loop (residues 348–364) of the thrombin B chain (residues 321–
579), that contains important structural features like the active
site His363, the carbohydrate attachment site at Asn373 and
the loop B sequence (residues 367–375) [9]. The histidine
disulphide loop is known to be a conserved region in the serine
protease domains of thrombin and homologous proteins [9].
Alignment of aminoacid sequences from 24 homologous
prothrombins or related serine proteases shows that Ala362
is conserved in all of them. This indicates its importance to the
structure of thrombin. The possible effect of this mutation on
the crystal structure of human a-thrombin is detailed in Fig. 4.
Further more, Ala362 fi Thr was found to introduce addi-
tional hydrogen bonds with Ile406 and Tyr410 in human
prothrombin. These structural perturbations in the mutant
probably interfere with the autocatalytic cleavage of a-throm-
bin (Arg284-Thr285; Arg155-Ser156) or with the FXa activa-
tion (Arg320-Ile321) of prothrombin to thrombin as has been
recently suggested for a Gly330Ser mutation [28]. However
Exon 8+9
BL-90BL-154 NC
Fig. 3. Representative gel photograph of conformation sensitive gel
electrophoresis (CSGE) analysis for polymerase chain reaction (PCR)
(exonic) fragment 8 + 9 of prothrombin gene: Patient PCRproducts were
mixed with equal volume of normal control (NC) PCR product and
analyzed in a 10% CSGE gel. The abnormal mobility of patient PCR
product relative to a normal control is shown by an arrow. Shown here are
a G fi A transition at nucleotide 7509 (Glu309 fi Lys) in patient BL-154
and 7484/7489 del GAA (Del Lys 301/302) mutation in patient BL-90.
Fig. 4. Close-up of a region of Ala362 [PDB: 1 ppb, Chymotrypsinogen
numbering (CT): 56] in human a-thrombin. Ala362 (shown in green) is a
hydrophobic aminoacid located buried (Solvent accessibility-0 [9]) in the
hydrophobic stretch between aminoacids Trp357 (CT: 51) to Leu365
(CT: 59) involving b-strand D in the serine protease domain. Alanine at
codon 362 is spatially close to the catalytic triad residue His363 (CT: 57)
and is hydrogen bonded to Ala361 (CT: 55), Cys364 (CT: 58), Leu365
(CT: 59), Leu366 (CT: 60), Ile406 (CT: 90), Asp419 (CT: 102) and Ile420
(CT: 103). This hydrophobic environment is further enhanced by the
presence of a buried disulfide bridge between adjacent residue Cys364 and
Cys348 (CT: 42). The replacement of Ala362 by threonine is likely to cause
structural changes in this region. The side chain of threonine is much larger
than alanine. As a result a conformational change in this region is likely
between Trp357-Leu365 which contains His363 that is a part of the active
site catalytic triad (Asp419 and Ser525) and also contains cysteine 364
which is disulfide bonded to cysteine at 348.
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further studies are needed to demonstrate the functional effect
of this mutation. The reported identification of a topologically
equivalent Ala220 fi Val mutation in factor IX gene to cause
hemophilia B [29], also provides evidence that mutations in this
codon are pathognomic.
An Arg-1 fi Gln change was detected in a compound
heterozygous state with the novel Ala362 fi Thr mutation.
Arg-1 fi Gln change has been reported [9] in a homozygous
condition in an Iranian patient presenting with severe bleeding
symptoms. This substitution involves the replacement of a
highly basic residue by an uncharged hydrophilic aminoacid
[9]. It affects a highly conserved recognition sequence (-2Arg-
Arg-Ala-Asn+2) for a propeptidase, furin. This recognition
motif is present in all the six vitamin K dependent clotting
factors namely prothrombin, factors VII, IX, X, protein C and
S. A mutation at this site has been therefore postulated to
abolish the cleavage of propeptide from mature prothrombin
during its biosynthesis [9].
An Arg271 fi Cys mutation was associated with a FII: C of
10.2% and severe bleeding symptoms in one of our patients.
This mutation has been demonstrated in a Japanese patient
with a similar severe phenotype and a corresponding coagulant
activity of 18% (Prothrombin Obihiro) [25]. The prothrombin
in this case has been reported to be dysfunctional, as the
Arg271 fi Cys mutation is located at a factor Xa cleavage site
(Arg271-Thr272). Prothrombins Madrid [30] and Barcelona
[31] also have identical Arg271 fi Cys mutation, while
prothrombins Padua [32] and Dhahran [33] have an
Arg271 fi His substitution. All these mutations are known
to affect the activation of the prothrombin by factor Xa and
subsequent generation of thrombin to cause excessive bleeding
in these patients. Although a majority of the polymorphisms
(Table 2) identified in our patient (BL-154) were reported in the
Japanese patient, this mutation is likely to have an independent
origin for two reasons. A novel 4304insG polymorphism was
identified only in our patient and secondly, this mutation had
occurred at a CpG dinucleotide which is known hotspots for
spontaneous demethylation of cytosine to thymidine nucleotide
[25].
The in-frame deletion of one of the lysine residues at codon
301 or 302 found in this series has been reported among two
Iranian kindred [9]. All these patients are characterized by
severe bleeding symptoms. This mutation has been recently
shown by expression studies to have a 20-fold decreased
interaction with anti-thrombin, significantly reduced sensitivity
to sodium ion, defective platelet activating receptor 1 activa-
tion, decreased interaction with protein C.Molecular dynamics
simulation of the mutant thrombin in full explicit water solvent
provided support to the role of the mutant A-chain in affecting
conformation and catalytic properties of the B-chain, as well as
in the geometry of the catalytic triad residues [34]. This
in-frame deletion is consistent with a status of hypoprothrom-
binemia (FII: C of 1% and 7% observed in Iranians and 4.7%
in Indian patient).
The substitution of glutamic acid at codon 309 by lysine
corresponded to mild bleeding symptoms. Glu309 fi Lys
(Prothrombin Denver II) has been shown to be associated
with severe bleeding in a patient of Caucasian origin [35] when
present in a compound heterozygous state with Glu300 fi Lys
substitution (Prothrombin Denver I). Glu309 residue has been
described [35] as part of an A1 amphiphilic a-helix in the serine
protease, with these hydrophobic residues interacting with the
thrombin heavy chain. A change of negatively charged Glu309
for a positively charged Lys is believed to disrupt this structure
and affect normal folding of the molecule. It has been
hypothesized that this mutation could interfere with the
autocatalytic cleavage of the A-chain of thrombin or factor
Xa activation [35].
In conclusion, this report describes the mutations in four
unrelated patients with inherited prothrombin deficiency
adding significantly to the data on the molecular basis of this
condition.
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